39, Dalton Street

Boston,

Massachusetts,

USA,

ZIP: 02199

Phone: +1 617 455 4188

Dedicated to Realizing the Commercial Potential of Gene Therapies

The closing weeks of 2021 marked a historic approval for Spark Therapeutics and a watershed moment for the reinvigorated gene therapy field. This first will undoubtedly not be the last time that gene therapies have a huge impact on rare disease sufferers.

Gene Therapy for Rare Disorders 2021 will equip you with the insights to make the most of this unprecedented opportunity. Rather than attempting to cover the entire cell and gene therapy world, this meeting will focus specifically on the critical clinical, manufacturing, regulatory and reimbursement challenges involved in delivering gene therapies to market.

Leaders from the likes of Spark, FDA, Pfizer, GSK and Bluebird Bio will deliver in-depth insights into the work that has underpinned their success, enabling you to maximize the commercial potential of your gene therapy products.

Join your colleagues at this uniquely focused event to ensure you’re making the right decisions with your gene therapy pipeline at such a pivotal time for the field.

Early booking discounts are available in addition to group rates. For more information, visit the website. 

URLs:

Brochure https://go.evvnt.com/178854-1?pid=1052
Booking https://go.evvnt.com/178854-2?pid=1052
Tickets https://go.evvnt.com/178854-3?pid=1052

Speakers: Katherine High (Spark Therapeutics), Philip Gregory (Bluebird Bio), Steven Paul (Voyager Therapeutics), Jude Samulski (Pfizer), Steven Zelenkofske (uniQure), Mary Dunkle (NORD), Sven Kili (GSK), Olivier Danos (REGENXBIO), and Gumei Liu (FDA)